A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients
Status:
Terminated
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
The objectives of this study are:
- To determine the safety and MTD of CPI-613, when used in combination with Gemcitabine,
in cancer patients.
- To compare the safety and efficacy of CPI-613/Gemcitabine combination vs. Gemcitabine
alone in patients with carcinoma of the pancreas.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Cornerstone Pharmaceuticals, Inc. Rafael Pharmaceuticals Inc.